89 related articles for article (PubMed ID: 11605006)
1. Presence of antibodies against retinoblastoma tumor suppressor protein in patients with lung cancer.
Matsumoto S; Teramoto H; Nakamoto M; Igishi T; Kawasaki Y; Shimizu E
Int J Oncol; 2001 Nov; 19(5):1035-9. PubMed ID: 11605006
[TBL] [Abstract][Full Text] [Related]
2. Analysis of antibodies to p16INK4A tumor suppressor gene products in lung cancer patients.
Namikawa O; Shimizu E; Sumitomo K; Sone S
Int J Oncol; 1999 Apr; 14(4):681-5. PubMed ID: 10087314
[TBL] [Abstract][Full Text] [Related]
3. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients.
Yamamoto A; Shimizu E; Ogura T; Sone S
Int J Cancer; 1996 Aug; 69(4):283-9. PubMed ID: 8797869
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival.
Winter SF; Sekido Y; Minna JD; McIntire D; Johnson BE; Gazdar AF; Carbone DP
J Natl Cancer Inst; 1993 Dec; 85(24):2012-8. PubMed ID: 8246287
[TBL] [Abstract][Full Text] [Related]
6. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
7. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
[TBL] [Abstract][Full Text] [Related]
8. Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients.
Yamamoto A; Shimizu E; Takeuchi E; Houchi H; Doi H; Bando H; Ogura T; Sone S
Oncology; 1999; 56(2):129-33. PubMed ID: 9949299
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction.
Lu Y; Boss JM; Hu SX; Xu HJ; Blanck G
J Immunol; 1996 Apr; 156(7):2495-502. PubMed ID: 8786310
[TBL] [Abstract][Full Text] [Related]
10. Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients.
Shih NY; Lai HL; Chang GC; Lin HC; Wu YC; Liu JM; Liu KJ; Tseng SW
Jpn J Clin Oncol; 2010 Jul; 40(7):663-9. PubMed ID: 20395242
[TBL] [Abstract][Full Text] [Related]
11. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Shijubo Y; Abe S; Hirohashi Y; Torigoe T; Sato N; Watanabe N
Lung Cancer; 2005 May; 48(2):217-21. PubMed ID: 15829321
[TBL] [Abstract][Full Text] [Related]
12. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.
Kelley MJ; Nakagawa K; Steinberg SM; Mulshine JL; Kamb A; Johnson BE
J Natl Cancer Inst; 1995 May; 87(10):756-61. PubMed ID: 7563154
[TBL] [Abstract][Full Text] [Related]
13. Recoverin as a paraneoplastic antigen in lung cancer: the occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors.
Bazhin AV; Savchenko MS; Shifrina ON; Demoura SA; Chikina SY; Jaques G; Kogan EA; Chuchalin AG; Philippov PP
Lung Cancer; 2004 May; 44(2):193-8. PubMed ID: 15084384
[TBL] [Abstract][Full Text] [Related]
14. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma.
Xu HJ; Quinlan DC; Davidson AG; Hu SX; Summers CL; Li J; Benedict WF
J Natl Cancer Inst; 1994 May; 86(9):695-9. PubMed ID: 8158700
[TBL] [Abstract][Full Text] [Related]
15. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.
Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K
Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
[TBL] [Abstract][Full Text] [Related]
17. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
Stich O; Klages E; Bischler P; Jarius S; Rasiah C; Voltz R; Rauer S
Acta Neurol Scand; 2012 May; 125(5):326-31. PubMed ID: 21751968
[TBL] [Abstract][Full Text] [Related]
18. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
19. Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Tateishi R
Oncology; 1994; 51(6):544-51. PubMed ID: 7970501
[TBL] [Abstract][Full Text] [Related]
20. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma.
Shimizu E; Coxon A; Otterson GA; Steinberg SM; Kratzke RA; Kim YW; Fedorko J; Oie H; Johnson BE; Mulshine JL
Oncogene; 1994 Sep; 9(9):2441-8. PubMed ID: 8058306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
